Intraductal Carcinoma Predicts Poor Response to Neoadjuvant Therapy in High-risk Prostate Cancer: A Retrospective Analysis of a Prospective Trial
Intraductal carcinoma (IDC) is a more aggressive form of prostate cancer that does not respond well to treatment. In our study, we found that 91% of patients who had IDC detected in their biopsy before surgery did not show a good response to presurgery therapy.
Authors
- Neil Fleshner (ORCID: https://orcid.org/0000-0001-7407-7463)
- Rosette Veloso (ORCID: https://orcid.org/0009-0008-5612-7015)
- Jessica Cockburn (ORCID: https://orcid.org/0000-0001-6308-0923)
- Pocharapong Jenjitranant (ORCID: https://orcid.org/0000-0002-5865-8820)
- Eric Winquist (ORCID: https://orcid.org/0000-0002-8829-5979)
- Theodorus van der Kwast (ORCID: https://orcid.org/0000-0001-8640-5786)
- Rui Henrique (ORCID: https://orcid.org/0000-0003-3171-4666)
- Rune Matthiesen (ORCID: https://orcid.org/0000-0002-6353-2616)
- Katherine Lajkosz (ORCID: https://orcid.org/0000-0003-3760-5401)
- Clare O’Connell
- Anthony M. Joshua (ORCID: https://orcid.org/0000-0001-5159-4580)
- Andrea Delgado Benitez
- Rui Bernardino (ORCID: https://orcid.org/0000-0001-8076-4550)
- David‐Dan Nguyen (ORCID: https://orcid.org/0000-0001-5570-8792)
- Leyi Yin
Institutions
- Western University (CA)
- Garvan Institute of Medical Research (AU)
- University of Toronto (CA)
- Mahidol University (TH)
- Princess Margaret Cancer Centre (CA)
- Instituto Português de Oncologia Francisco Gentil (PT)
- Ramathibodi Hospital (TH)
- The Kinghorn Cancer Centre (AU)
- Universidade Nova de Lisboa (PT)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.euros.2025.09.015
- Citations
- 2
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04